

Vasily N Sukhorukov

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2544092/publications.pdf>

Version: 2024-02-01

60
papers

578
citations

759233

12
h-index

713466

21
g-index

63
all docs

63
docs citations

63
times ranked

731
citing authors

#	ARTICLE	IF	CITATIONS
1	Modulating mTOR Signaling as a Promising Therapeutic Strategy for Atherosclerosis. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1153.	4.1	11
2	Cholesterol Transport Dysfunction and Its Involvement in Atherogenesis. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1332.	4.1	13
3	Interplay between Zn ²⁺ Homeostasis and Mitochondrial Functions in Cardiovascular Diseases and Heart Ageing. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6890.	4.1	15
4	Aging of Vascular System Is a Complex Process: The Cornerstone Mechanisms. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6926.	4.1	2
5	The Role of Mitochondrial Abnormalities in Diabetic Cardiomyopathy. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7863.	4.1	14
6	Pathophysiological Aspects of the Development of Abdominal Aortic Aneurysm with a Special Focus on Mitochondrial Dysfunction and Genetic Associations. <i>Biomolecular Concepts</i> , 2021, 12, 55-67.	2.2	6
7	Do Mitochondrial DNA Mutations Play a Key Role in the Chronification of Sterile Inflammation? Special Focus on Atherosclerosis. <i>Current Pharmaceutical Design</i> , 2021, 27, 276-292.	1.9	5
8	Modern Concepts of Molecular Biology in Search of Biomarkers for Laboratory Diagnostics and Drug Therapy of Non-infectious Diseases. <i>Current Pharmaceutical Design</i> , 2021, 27, 141-142.	1.9	1
9	Pro-inflammatory molecules induce cholesterol accumulation in macrophages: Role of inflammatory response in foam cell formation. <i>Atherosclerosis</i> , 2021, 320, 129-130.	0.8	0
10	Genetic and Epigenetic Biomarkers for Diagnosis, Prognosis and Treatment of Metabolic Syndrome. <i>Current Pharmaceutical Design</i> , 2021, 27, 3729-3740.	1.9	9
11	The effect of interleukins on the accumulation of cholesterol in macrophages obtained from donors. <i>Atherosclerosis</i> , 2021, 331, e71.	0.8	0
12	Morphological characteristics of thoracic aortic aneurysms. <i>Atherosclerosis</i> , 2021, 331, e246.	0.8	0
13	The interplay between ER stress, inflammation, and lipid metabolism. <i>Atherosclerosis</i> , 2021, 331, e134.	0.8	0
14	Approach to edit mitochondrial DNA mutations associated with atherosclerosis. <i>Atherosclerosis</i> , 2021, 331, e70-e71.	0.8	1
15	Molecular Targets Used for Diagnostics, Treatment and Prediction of Somatic Diseases: Special Focus on Tumor Stroma Biomarkers. <i>Current Pharmaceutical Design</i> , 2021, 27, 3083-3083.	1.9	0
16	Thoracic Aortic Aneurysm: Blood Pressure and Inflammation as Key Factors in the Development of Aneurysm Dissection. <i>Current Pharmaceutical Design</i> , 2021, 27, 3122-3127.	1.9	14
17	Genetic and Epigenetic Biomarkers for Diagnosis, Prognosis, and Treatment of Global Diseases. <i>Current Pharmaceutical Design</i> , 2021, 27, 3667-3667.	1.9	0
18	Molecular Pathogenesis and the Possible Role of Mitochondrial Heteroplasmy in Thoracic Aortic Aneurysm. <i>Life</i> , 2021, 11, 1395.	2.4	1

#	ARTICLE	IF	CITATIONS
19	A Novel Insight at Atherogenesis: The Role of Microbiome. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 586189.	3.7	19
20	Endoplasmic Reticulum Stress in Macrophages: The Vicious Circle of Lipid Accumulation and Pro-Inflammatory Response. <i>Biomedicines</i> , 2020, 8, 210.	3.2	23
21	Microarray analysis of peripheral blood monocytes in patients with familial hypercholesterolemia and peripheral artery disease. <i>Atherosclerosis</i> , 2020, 315, e188-e189.	0.8	0
22	Approach to the creation of mitochondrial therapy of atherosclerosis. <i>Atherosclerosis</i> , 2020, 315, e186.	0.8	0
23	Lipid Metabolism in Macrophages: Focus on Atherosclerosis. <i>Biomedicines</i> , 2020, 8, 262.	3.2	57
24	Thoracic Aortic Aneurysm and Factors Affecting Aortic Dissection. <i>Journal of Personalized Medicine</i> , 2020, 10, 153.	2.5	11
25	Current Trends in Vascular Biology and Atherothrombosis. <i>Current Pharmaceutical Design</i> , 2020, 26, 6-10.	1.9	1
26	Signaling Pathways and Key Genes Involved in Regulation of foam Cell Formation in Atherosclerosis. <i>Cells</i> , 2020, 9, 584.	4.1	67
27	Role of Phagocytosis in the Pro-Inflammatory Response in LDL-Induced Foam Cell Formation; a Transcriptome Analysis. <i>International Journal of Molecular Sciences</i> , 2020, 21, 817.	4.1	17
28	Signaling Pathways Potentially Responsible for Foam Cell Formation: Cholesterol Accumulation or Inflammatory Response? What is First?. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2716.	4.1	16
29	Medicinal Plants as a Potential and Successful Treatment Option in the Context of Atherosclerosis. <i>Frontiers in Pharmacology</i> , 2020, 11, 403.	3.5	34
30	Cholesterol metabolism in macrophages. <i>Complex Issues of Cardiovascular Diseases</i> , 2020, 9, 91-101.	0.5	4
31	Prevention of atherosclerosis the role of special diets and functional foods. <i>Frontiers in Bioscience - Scholar</i> , 2020, 12, 57-69.	2.1	1
32	Cell and tissue markers of atherosclerosis. <i>Complex Issues of Cardiovascular Diseases</i> , 2020, 9, 102-113.	0.5	1
33	The role of endoplasmic reticulum stress in atherosclerosis. <i>Complex Issues of Cardiovascular Diseases</i> , 2020, 9, 88-94.	0.5	0
34	Atherosclerosis prevention the role of special diets and functional food. <i>Frontiers in Bioscience - Elite</i> , 2020, 12, 95-101.	1.8	1
35	Master regulators in the foam cell formation; the role of phagocytosis. <i>European Heart Journal</i> , 2020, 41, .	2.2	0
36	Heteroplasmic Variants of Mitochondrial DNA in Atherosclerotic Lesions of Human Aortic Intima. <i>Biomolecules</i> , 2019, 9, 455.	4.0	13

#	ARTICLE	IF	CITATIONS
37	The Role Of Effector Proteins In Cellular Cholesterol Efflux. <i>Atherosclerosis</i> , 2019, 287, e222.	0.8	0
38	Genetic and Molecular Approaches to Drug Target Discovery for Treatment of the most Dangerous Diseases that are Rapidly Increasing Globally. Part II. <i>Current Pharmaceutical Design</i> , 2019, 25, 625-626.	1.9	0
39	Genetic and Molecular Approaches to Drug Target Discovery for Treatment of the most Dangerous Diseases that are Rapidly Increasing Globally. Part I. <i>Current Pharmaceutical Design</i> , 2019, 25, 211-212.	1.9	0
40	Glycosylation of human plasma lipoproteins reveals a high level of diversity, which directly impacts their functional properties. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2019, 1864, 643-653.	2.4	19
41	Transcriptional Characteristics of Activated Macrophages. <i>Current Pharmaceutical Design</i> , 2019, 25, 213-217.	1.9	10
42	Inhibitors of DNA Methylation and Histone Deacetylation as Epigenetically Active Drugs for Anticancer Therapy. <i>Current Pharmaceutical Design</i> , 2019, 25, 635-641.	1.9	12
43	The role of physical activity in the development of atherosclerotic lesions of the vascular wall. <i>Clinical and Experimental Morphology</i> , 2019, 8, 25-31.	0.2	2
44	Translation of Basic Research into Clinical Practice: Focus on Cell-Based Diagnostics and Therapy. <i>Current Pharmaceutical Design</i> , 2018, 24, 3005-3007.	1.9	0
45	Current Approaches to Diagnostics and Therapies of Chronic Diseases: Focus on Molecular and Cell Biology. <i>Current Pharmaceutical Design</i> , 2018, 24, 2757-2759.	1.9	0
46	Transcriptome analysis of human macrophages reveals genes regulating cellular cholesterol efflux. <i>Atherosclerosis</i> , 2018, 275, e48.	0.8	0
47	HDL activates expression of genes stimulating cholesterol efflux in human monocyte-derived macrophages. <i>Experimental and Molecular Pathology</i> , 2018, 105, 202-207.	2.1	11
48	Unsaturated, low-abundant species of HDL (Lyso)phospholipids are most affected by ST segment elevation myocardial infarction. <i>Atherosclerosis</i> , 2018, 275, e56-e57.	0.8	0
49	Diagnostics and Therapy of Human Diseases - Focus on Sialidases. <i>Current Pharmaceutical Design</i> , 2018, 24, 2870-2875.	1.9	6
50	Analysis of Apolipoprotein B Protein of Circulating Multiple-Modified Low-Density Lipoprotein. <i>International Journal of Angiology</i> , 2017, 26, 049-052.	0.6	2
51	Sialylation of human plasma lipoproteins as a key determinant of biological function. <i>Atherosclerosis</i> , 2017, 263, e91-e92.	0.8	0
52	Poor glycemic control in type 2 diabetes enhances functional and compositional alterations of small, dense HDL3c. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2017, 1862, 188-195.	2.4	31
53	Sialidases: Therapeutic and Antiatherogenic Potential. <i>Current Pharmaceutical Design</i> , 2017, 23, 4696-4701.	1.9	8
54	HDL-Targeting Therapeutics: Past, Present and Future. <i>Current Pharmaceutical Design</i> , 2017, 23, 1207-1215.	1.9	17

#	ARTICLE	IF	CITATIONS
55	Multiple-modified Low-Density Lipoprotein as Atherogenic Factor of Patients'; Blood: Development of Therapeutic Approaches to Reduce Blood Atherogenicity. <i>Current Pharmaceutical Design</i> , 2017, 23, 932-936.	1.9	13
56	Carbohydrate composition of circulating multiple-modified low-density lipoprotein. <i>Vascular Health and Risk Management</i> , 2016, Volume 12, 379-385.	2.3	9
57	Epigenetic factors in atherogenesis: MicroRNA. <i>Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry</i> , 2016, 10, 269-275.	0.4	0
58	Lipid composition of circulating multiple-modified low density lipoprotein. <i>Lipids in Health and Disease</i> , 2016, 15, 134.	3.0	35
59	Neuron density in the hippocampus in rat strains with contrasting nervous system excitability after prolonged emotional-pain stress. <i>Neuroscience and Behavioral Physiology</i> , 2008, 38, 355-357.	0.4	6
60	Chemical composition of circulating native and desialylated low density lipoprotein: what is the difference?. <i>Vessel Plus</i> , 0, , .	0.4	23